Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
281 questions in 50 reviews · Gynaecological, Neuro-oncology and Orphan Cancer
current versionsNo studies 281 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings 2: PLD alone vs other conventional chemotherapy Quality of life · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings 3: PLD with chemotherapy vs PLD alone Quality of life · adult women with recurrent platinum‐resistant epithelial ovarian cancer Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone Bowel fistula / perforation (grade ≥ 3) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone Quality of life (QoL) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone Hypertension grade ≥ 3 · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone Bowel fistula / perforation (grade ≥ 3) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone Hypertension (grade ≥ 2) · recurrent platinum‐sensitive EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone Bowel fistula / perforation (grade ≥ 3) · recurrent platinum‐sensitive EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone Any adverse events (grade ≥ 3) · recurrent platinum‐sensitive EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone Hypertension (grade ≥ 2) · recurrent platinum‐sensitive EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone Bowel fistula/perforation (grade ≥ 3) · recurrent platinum‐sensitive EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with bevacizumab vs chemotherapy alone Quality of life · recurrent platinum‐resistant EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI vs chemotherapy alone Hypertension (grade ≥ 2)Â · recurrent platinum‐resistant EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone Any adverse events (grade ≥3)Â · recurrent EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone Hypertension (grade ≥ 2)Â · recurrent EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy with bevacizumab followed by maintenance bevacizumab vs chemotherapy alone Bowel fistula / perforation (grade ≥ 3) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane | no estimate extracted | NR | No studies |
Exercise intervention vs no exercise intervention Overall survival · adults with breast or prostate cancer receiving radiation therapy alone Exercise interventions for adults with cancer receiving radiation therapy alone (2023) · Cochrane | no estimate extracted | NR | No studies |
Exercise intervention vs no exercise intervention Return to work · adults with breast or prostate cancer receiving radiation therapy alone Exercise interventions for adults with cancer receiving radiation therapy alone (2023) · Cochrane | no estimate extracted | NR | No studies |
Ultra‐radical (extensive) surgery vs standard surgery Recurrence rate · women with stage IIIc or IV ovarian cancer Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced… (2022) · Cochrane | no estimate extracted | NR | No studies |
Ultra‐radical (extensive) surgery vs standard surgery (Loco)regional control · women with stage IIIc or IV ovarian cancer Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced… (2022) · Cochrane | no estimate extracted | NR | No studies |
Ultra‐radical (extensive) surgery vs standard surgery Quality of Life · women with stage IIIc or IV ovarian cancer Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced… (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone Outcomes · newly‐diagnosed EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy Outcomes · platinum‐sensitive recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo after chemotherapy (maintenance therapy) Outcomes · platinum‐sensitive recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone Overall survival ‐ not reported · newly‐diagnosed EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone Outcomes · platinum‐sensitive recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone Quality of Life ‐ not reported · platinum‐sensitive recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy Outcomes · platinum‐resistant recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy Overall survival ‐ not reported · platinum‐resistant recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy Progression‐free survival ‐ not reported · platinum‐resistant recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy Quality of Life ‐ not reported · platinum‐resistant recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy) Outcomes · newly‐diagnosed EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel Quality of Life ‐ not measured · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel Alopecia ‐ not reported · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel Quality of Life ‐ not measured · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel Neutropenia ‐ not reported · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel Alopecia ‐ not measured · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Weekly paclitaxel vs three‐weekly paclitaxel Quality of Life ‐ not reported · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Hysterectomy (simple or radical) with radiotherapy vs radiotherapy alone Quality of life · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Hysterectomy (simple or radical) with chemoradiotherapy vs chemoradiotherapy alone Quality of life · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Hysterectomy (simple or radical) with chemoradiotherapy vs chemoradiotherapy alone Severe/serious adverse events · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Hysterectomy (simple or radical) with chemoradiotherapy vs internal radiotherapy (brachytherapy) with chemoradiotherapy Quality of life · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Hysterectomy (radical) with neoadjuvant chemotherapy vs chemoradiotherapy alone Quality of life · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Hysterectomy (simple or radical) with neoadjuvant chemotherapy vs radiotherapy alone Quality of life · women with locally advanced cervical cancer Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Test · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Test · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on… Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in… (2022) · Cochrane | no estimate extracted | NR | No studies |
Dexrazoxane vs no cardioprotective intervention or placebo Secondary malignant neoplasms · adults with cancer receiving anthracyclines Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Dexrazoxane vs no cardioprotective intervention Progression‐free survival · children with cancer receiving anthracyclines Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Dexrazoxane vs no cardioprotective intervention Quality of life · children with cancer receiving anthracyclines Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |
Dexrazoxane vs no cardioprotective intervention or placebo Quality of life · adults with cancer receiving anthracyclines Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving… (2022) · Cochrane | no estimate extracted | NR | No studies |